Vydura®▼ (rimegepant) Prescribing Information (PI) for Great Britain (GB) and Northern Ireland (NI)
Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
touchFEATURE Current oral migraine therapy: targeting calcitonin gene-related peptide (CGRP)
This site is intended for UK healthcare professionals only.
In this series of three short, animated features, learn about the role of CGRP in the pathophysiology of migraine, and how Vydura®▼(rimegepant), a small molecule CGRP receptor antagonist, may help manage this condition.
Vydura® (rimegepant): mode of action
Learn about the burden and pathophysiology of migraine in this short, animated video, and how the small molecule CGRP receptor antagonist Vydura®▼ (rimegepant) works for the acute treatment of migraine or the preventive treatment of migraine.
Adverse Events
Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
1/3 Next Chapter
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised phase 3, double-blind, placebo-controlled trial
Review key clinical trial evidence demonstrating how the small molecule CGRP receptor antagonist Vydura®▼ (rimegepant) can relieve the symptoms of acute migraine.
Adverse Events
Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
Review key clinical trial evidence demonstrating how the small molecule CGRP receptor antagonist Vydura®▼ (rimegepant) can help prevent migraine in people who have at least 4 migraine attacks per month.
Adverse Events
Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
Adverse Events
Adverse Events
Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
Overview & Learning Objectives
Overview
Migraine is a chronic neurovascular disease that affects ~1 billion people worldwide.1 In this series of three short animations, the role of CGRP in the pathophysiology of migraine is explained, and how the small molecule CGRP receptor antagonist Vydura® ▼(rimegepant) works. Vydura® is indicated for:
- Acute treatment of migraine with or without aura in adults2
- Preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month2
Learning Objectives
After watching this activity, participants should be better able to:
- Understand the role of CGRP in the pathophysiology of migraine
- Describe how rimegepant, a small molecule CGRP antagonist, can help treat migraine
- Describe key clinical trial data supporting the use of Vydura® ▼(rimegepant) for the treatment of acute migraine or the prevention of episodic migraine
References
- Ashina M, et al. Lancet. 2021;397:1485–1495.
- Vydura® (rimegepant) Summary of Products Characteristics for Great Britain, Vydura® (rimegepant) Summary of Products Characteristics for Northern Ireland (NI).